Literature DB >> 29321180

Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth.

Olivier Baud1,2, Clémence Trousson1, Valérie Biran1,3, Emilie Leroy1, Damir Mohamed4, Corinne Alberti4.   

Abstract

OBJECTIVE: To determine whether early hydrocortisone treatment in extremely preterm infants affects neurodevelopmental outcomes at 2 years of age according to gestational age at birth. PATIENTS AND METHODS: This is an exploratory analysis of neurodevelopmental outcomes by gestational age strata from the PREMILOC trial, in which patients were randomly assigned to receive either placebo or low-dose hydrocortisone and randomisation was stratified by gestational age groups (24-25 and 26-27 weeks of gestation). Neurodevelopmental impairment (NDI) was assessed using a standardised neurological examination and the revised Brunet-Lézine scale at 22 months of corrected age.
RESULTS: A total of 379 of 406 survivors were evaluated, 96/98 in the gestational age group of 24-25 weeks and 283/308 in the gestational age group of 26-27 weeks. Among surviving infants born at 24-25 weeks, significant improvement in global neurological assessment was observed in the hydrocortisone group compared with the placebo group (P=0.02) with a risk of moderate-to-severe NDI of 2% and 18%, respectively (risk difference 16 (95% CI -28% to -5%)). In contrast, no statistically significant difference between treatment groups was observed in infants born at 26-27 weeks (P=0.95) with a similar risk of moderate-to-severe NDI of 9% in both groups. The incidence of cerebral palsy or other major neurological impairments were found similar between treatment groups in each gestational group.
CONCLUSIONS: In an exploratory analysis of neurodevelopmental outcomes from the PREMILOC trial, early low-dose hydrocortisone was associated with a statistically significant improvement in neurodevelopmental outcomes in infants born at 24 and 25 weeks of gestation. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  extremely preterm neonate; hydrocortisone; neurodevelopmental impairment

Mesh:

Substances:

Year:  2018        PMID: 29321180     DOI: 10.1136/archdischild-2017-313756

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  11 in total

Review 1.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

Review 2.  Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants.

Authors:  Brigitte Lemyre; Michael Dunn; Bernard Thebaud
Journal:  Paediatr Child Health       Date:  2020-08-01       Impact factor: 2.253

3.  Duration of mechanical ventilation is more critical for brain growth than postnatal hydrocortisone in extremely preterm infants.

Authors:  Chloé Rousseau; Marine Guichard; Elie Saliba; Baptiste Morel; Geraldine Favrais
Journal:  Eur J Pediatr       Date:  2021-05-16       Impact factor: 3.183

4.  Behavioural dysfunctions of 10-year-old children born extremely preterm associated with corticotropin-releasing hormone expression in the placenta.

Authors:  Alan Leviton; Elizabeth N Allred; Robert M Joseph; Thomas Michael O'Shea; Joseph Majzoub; Karl C K Kuban
Journal:  Acta Paediatr       Date:  2018-08-07       Impact factor: 2.299

Review 5.  Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia.

Authors:  Zeyar T Htun; Elizabeth V Schulz; Riddhi K Desai; Jaime L Marasch; Christopher C McPherson; Lucy D Mastrandrea; Alan H Jobe; Rita M Ryan
Journal:  J Perinatol       Date:  2021-05-19       Impact factor: 2.521

Review 6.  An Immature Science: Intensive Care for Infants Born at ≤23 Weeks of Gestation.

Authors:  Matthew A Rysavy; Katrin Mehler; André Oberthür; Johan Ågren; Satoshi Kusuda; Patrick J McNamara; Regan E Giesinger; Angela Kribs; Erik Normann; Susan J Carlson; Jonathan M Klein; Carl H Backes; Edward F Bell
Journal:  J Pediatr       Date:  2021-03-07       Impact factor: 6.314

7.  Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial.

Authors:  Yuan He; Yong Zhang; Shuqiang Gao; Xiaoling Wang; Na He; Deshuang Zhang; Wenbin Dong; Christian Wieg; Xiaoping Lei
Journal:  Trials       Date:  2020-09-03       Impact factor: 2.279

8.  Systematic review and meta-analysis: the effect of bronchopulmonary dysplasia on neurodevelopment in very low birth weight premature infants.

Authors:  Shuqiang Gao; Xiaolong Zhang; Weina Du; Xiaofeng Zhou; Yufeng Xi; Rong Ju
Journal:  Transl Pediatr       Date:  2021-11

9.  Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.

Authors:  Viraraghavan Vadakkencherry Ramaswamy; Tapas Bandyopadhyay; Debasish Nanda; Prathik Bandiya; Javed Ahmed; Anip Garg; Charles C Roehr; Sushma Nangia
Journal:  JAMA Pediatr       Date:  2021-06-07       Impact factor: 16.193

Review 10.  Phenotypes of Bronchopulmonary Dysplasia.

Authors:  Shih-Hsin Wang; Po-Nien Tsao
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.